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SHORT ABSTRACT:  
The here described fluorescence-based calcium mobilization assay is a medium-throughput 
reverse pharmacology screening system for the identification of functionally activating ligand(s) 
of orphan G protein-coupled receptors (GPCRs). 
 
LONG ABSTRACT:  
For more than 20 years, reverse pharmacology has been the preeminent strategy to discover the 
activating ligands of orphan G protein-coupled receptors (GPCRs). The onset of a reverse 
pharmacology assay is the cloning and subsequent transfection of a GPCR of interest in a 
cellular expression system. The heterologous expressed receptor is then challenged with a 
compound library of candidate ligands to identify the receptor-activating ligand(s). Receptor 
activation can be assessed by measuring changes in concentration of second messenger reporter 
molecules, like calcium or cAMP. The fluorescence-based calcium mobilization assay described 
here is a frequently used medium-throughput reverse pharmacology assay. The orphan GPCR is 
transiently expressed in human embryonic kidney 293T (HEK293T) cells and a promiscuous 
Gα16 construct is co-transfected. Following ligand binding, activation of the Gα16 subunit induces 
the release of calcium from the endoplasmic reticulum. Prior to ligand screening, the receptor-
expressing cells are loaded with a fluorescent calcium indicator, Fluo-4 acetoxymethyl. The 
fluorescent signal of Fluo-4 is negligible in cells under resting conditions, but can be amplified 
more than a 100-fold upon the interaction with calcium ions that are released after receptor 
activation. The described technique does not require the time-consuming establishment of stably 
transfected cell lines in which the transfected genetic material is integrated into the host cell 
genome. Instead, a transient transfection, generating temporary expression of the target gene, is 
sufficient to perform the screening assay. The setup allows medium-throughput screening of 
hundreds of compounds. Co-transfection of the promiscuous Gα16, which couples to most 
GPCRs, allows the intracellular signaling pathway to be redirected towards the release of 
calcium, regardless of the native signaling pathway in endogenous settings. The HEK293T cells 
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are easy to handle and have proven their efficacy throughout the years in receptor 
deorphanization assays. However, optimization of the assay for specific receptors may remain 
necessary. 
 
INTRODUCTION: 
G protein-coupled receptors (GPCRs) constitute one of the largest and most diverse families 
among all cell surface proteins. Their presence in vertebrates, invertebrates, plants, yeast and 
slime mold, as well as in Protozoa and the earliest diploblastic Metazoa indicates that GPCRs are 
among the oldest molecules linked with signal transduction
1
. Their natural activating ligands 
comprise a wide diversity of external stimuli including peptides, biogenic amines, odorants, 
glycoproteins and photons
2
. As such, these receptor-ligand signaling systems are involved in a 
great variety of physiological processes. The broad functional spectrum makes them ideally 
suited for the development of therapeutic drugs that cover a wide range of human diseases. 
About 50-60% of the current drug targets are represented by GPCRs
3,4
. Besides their great 
importance in the pharmaceutical industry, GPCRs are also in the spotlight for the development 
of a new generation of species-specific insecticides
5,6
 and pesticides in general. Because the 
natural ligands of many GPCRs are still unidentified, they are classified as orphan GPCRs. The 
deorphanization of these receptors will improve the understanding of their physiological roles in 
organisms and may uncover putative targets for new drug applications
7
. 
 
Since the genomic era, the reverse pharmacology strategy is widely applied for the 
deorphanization of GPCRs
8. The approach implies that an orphan receptor is used as a ‘hook’ to 
‘fish out’ its activating ligand from a biological extract or from a library of synthetic compounds. 
The GPCR of interest is therefore cloned and subsequently transfected in a cellular expression 
system. In the most commonly used methods, receptor activation is determined by measuring 
changes in the concentration of second messenger molecules
9
. The main receptor screening 
assays rely on calcium-sensitive bioluminescent proteins (e.g. aequorin)
10
 or fluorescent calcium 
indicators (e.g. Fluo-4)
11
. The fluorescence-based assays, in which receptor-expressing cells are 
loaded with a fluorescent calcium indicator prior to ligand screening, have the advantage that 
they allow high-throughput screening due to their ease of use, short reading time, and the 
flexibility of screening multiple orphan receptors on a single plate
12
. 
 
Here, the fluorescence-based calcium mobilization assay is thoroughly described and illustrated 
by the deorphanization process of the Drosophila melanogaster short neuropeptide F (sNPF) 
receptor. This neuropeptidergic signaling system was originally characterized by Mertens et al. 
in 2002
13
 with a calcium bioluminescence assay performed in Chinese hamster ovary (CHO) 
cells
14
 and by Feng et al. in 2003 with an electrophysiological assay using Xenopus oocytes
15
. 
The presence of the sNPF signaling system seems to be limited to the phylum of Arthropoda, 
where it is implicated in a wide range of processes including the regulation of feeding, growth, 
stress reactions, locomotion and circadian rhythms
16
. 
 
Research on neuropeptidergic signaling systems in insects may not only lead to new targets for 
the development of insecticides, but the knowledge of their functioning may also be extrapolated 
towards other organisms as many signaling systems have been generally well conserved 
throughout evolution
17
. In the last decade, great progress has been made in the deorphanization 
process of insect neuropeptide GPCRs. Despite these efforts, only a small number of receptors 
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have been matched to their cognate ligand, and loads of sequence information for new orphan 
GPCRs has become available due to the booming of genomics
18
. The availability of 
medium/high-throughput screening approaches, like the fluorescence-based calcium mobilization 
assay that has proven to be a widely applied technique
9,18
, is therefore invaluable. 
 
The fluorescence-based calcium mobilization assay as described here is performed in the human 
embryonic kidney 293T (HEK293T) cell line and uses a fluorescent probe to determine changes 
in intracellular calcium concentrations upon receptor activation. To guarantee high expression 
and translation levels of the receptor, a Kozak consensus sequence
19
 is added to the 5’ end of the 
receptor-coding sequence, which is subsequently cloned in an expression vector (e.g. pcDNA 
vector series for mammalian cell lines). As it is difficult to predict the endogenous G protein-
coupling of an orphan GPCR based on sequence information alone, the second messenger 
molecules (e.g. calcium or cAMP) that are modulated after receptor activation often remain 
unknown prior to ligand identification. To circumvent this problem, promiscuous G proteins of 
the Gq family (e.g. murine Gα15 or human Gα16 [used here]) or chimeric G proteins (e.g. Gαqi5) 
that interact with most GPCRs and induce the release of calcium can be co-expressed
20,21,22
. 
Upon binding of the ligand to its receptor, the GPCR undergoes a conformational change which 
leads to the activation of specific intracellular pathways. The guanosine diphosphate (GDP) 
molecule, bound under resting conditions to the Gα16 subunit, will be replaced by a guanosine 
triphosphate (GTP) molecule. This provokes the dissociation of the heterotrimeric G protein in a 
Gα16 and Gβγ subunit. The Gα16 subunit activates phospholipase Cβ (PLCβ), which in turn 
hydrolyzes the membrane-bound phosphatidylinositol bisphosphate (PIP2) resulting in 
diacylglycerol (DAG) and inositol trisphosphate (IP3). IP3 will spread throughout the cytoplasm 
and activates IP3-dependent calcium channels present in the membrane of the endoplasmic 
reticulum, which induces the release of calcium into the cytoplasm. 
 
The calcium release upon receptor activation occurs within seconds and can be detected by 
loading cells before the screening assay with a calcium-sensitive dye, like Fluo-4 acetoxymethyl 
(AM)
11
. The AM ester group enables the fluorophore to cross the cell membrane and is cleaved 
off by cytoplasmic esterases once inside the cell. Consequently, the negative charges of the 
fluorescent dye are unmasked, preventing it from diffusing out of the cell and allowing it to 
interact with calcium ions. The fluorescent signal of Fluo-4 is negligible in cells under resting 
conditions only containing calcium concentrations in the nanomolar range. However, when 
calcium is released upon receptor activation, the signal can increase concentration-dependently 
to more than a 100-fold, hereby ensuring a large signal-to-noise ratio. Fluo-4 also exhibits a large 
dynamic range for reporting [calcium] around a Kd(calcium) of 345 nM, making it suitable to 
measure physiologically relevant calcium changes in a wide range of cells. The excitation of 
Fluo-4 occurs at 488 nm and the emission fluorescence is measured at 525 nm
11
. Fluorimeters 
like the fluorescence imaging plate reader (FLIPR)
23
, the NOVOstar or the FlexStation (station 
device)
12
 are medium/high-throughput systems that allow simultaneous compound addition and 
the detection of the Fluo-4 signal upon receptor activation for every well in an assay plate. The 
calcium mobilization assay described here relies on the station device 96-well microplate system. 
 
The SoftMax Pro software (software) is used to operate the station device as well as for data 
analysis. The program immediately displays the results as graphs in 96-well format. Multiple 
wells can be selected simultaneously to compare the outcome of these wells on the same graph. 
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The relative fluorescent unit (RFU) values of wells in each column are simultaneously measured 
for a period of two minutes, starting before the addition of compounds to the wells and 
continuing after measurement of the fluorescent signal following receptor activation. Typically, 
the trend of an agonist curve aligns with the baseline until an activating compound is added to 
the cells, resulting in a rapid increase of the fluorescent signal. The peak height is correlated with 
the final agonist concentration in the well. After the peak, the fluorescent signal slowly drops 
towards the baseline level. The RFU measurements can be converted into concentration-response 
curves to determine the EC50 value (half maximal effective concentration) of a ligand. In general, 
at least three independent screens, each including three replicas of a concentration series, should 
be performed to compose a reliable concentration-response curve. 
 
It is recommended to include several positive and negative controls in the experimental design. 
First of all, a transfection control, i.e. the implementation of a receptor with a known ligand, 
should be tested. This allows verifying whether the transfection agent was operational. 
Incorporation of a control experiment with an agonist for an endogenous receptor of the cell line 
and a negative control (e.g. wash buffer) are also recommended to monitor the health and 
viability of the cells and to exclude the possibility that the wash buffer was contaminated with a 
factor that could elicit an auto-fluorescent response. Frequently used agonists are a peptide 
derived from the protease-activated receptor-1 (PAR1), which acts as a PAR1 selective agonist, 
or carbachol which activates the acetylcholine receptor. Cells transfected with an empty 
expression vector should also be tested to exclude that active compounds interact with the cell’s 
endogenous receptors. Optimization of several parameters described in the protocol below may 
be required for different signaling systems. A schematic figure of the complete fluorescence-
based calcium mobilization assay is depicted in figure 1. 
 
[place figure 1 here] 
 
PROTOCOL: 
Note: All actions in which cells are involved should be carried out in a sterile environment by 
working in a laminar flow. 
 
1. Maintenance of the HEK293T cell line 
 
1.1) Grow the HEK293T cells in a T-75 flask at 37 °C in a 5% CO2 humidified incubator. 
 
1.2) Passage the cells when a confluence of 80% is reached. Note: This normally takes 3 to 4 
days. Cells in continuous culture allow 20-25 usable passages for screening. 
 
1.2.1) Place the Dulbecco’s phosphate buffered saline (PBS) without calcium chloride and 
magnesium chloride, PBS-trypsin-ethylenediaminetetraacetic acid (EDTA) (500 ml PBS 
supplemented with 10 ml trypsin-EDTA solution and 4.5 ml 4% EDTA) and growth medium 
(500 ml Dulbecco’s modified eagle’s medium – high glucose [DMEM] supplemented with 10% 
fetal bovine serum [FBS] and 1 mM penicillin-streptomycin [P-S]) at room temperature half an 
hour in advance. 
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1.2.2) Remove the old growth medium from the cells. Rinse off dead cells with 3 ml PBS and 
remove the PBS again. 
 
1.2.3) Add 3 ml PBS-trypsin-EDTA, incubate for 1 min at room temperature and remove the 
solution Note: The morphology of the cells will change from star-shaped to sphere-shaped. 
 
1.2.4) Loosen the cells from the bottom of the flask by gentle tapping and collect the cells by 
rinsing the bottom several times with 10 ml of fresh growth medium. 
 
1.2.5) Transfer 1 ml of the cell culture into a new T-75 flask containing 14 ml fresh growth 
medium, and incubate at 37 °C in a 5% CO2 humidified incubator. 
 
2. Transient transfection of HEK293T cells 
 
2.1) Grow the HEK293T cells in a T-75 flask 3 days before the actual calcium mobilization 
assay takes place. Make sure to use three T-75 flasks, one for transfection with the receptor 
construct, one for transfection with an empty expression vector, as negative control, and one for 
the transfection control. Note: the passaging of the cells is performed as described in step 1.2. 
When multiple 96-well plates have to be screened, T-150 flasks can be used to get a higher yield 
of cells (to do this, double all listed quantities in steps 1.2.4, 2.3, 3.1.2 and 3.1.3). 
 
2.2) Incubate the flasks at 37 °C in a 5% CO2 humidified incubator for 20 - 24 hr until the cell 
cultures approach 50-70% confluence. 
 
2.3) Co-transfect one population of cells with the expression vector encoding the GPCR of 
interest and the Gα16 construct, the second flask with the empty vector and the Gα16 construct, 
and the third with the transfection control and the Gα16 construct. Note: In this protocol, the 
Drosophila sNPF receptor was cloned in a pcDNA3.1 mammalian expression vector
13
. 
JetPRIME was used to perform the transfection, but other transfection reagents can be used as 
well. 
 
2.3.1) Add a total of 7.8 µg DNA (3.9 µg receptor construct or empty vector, and 3.9 µg Gα16 
expression construct) to a 1.5 ml microcentrifuge tube and add 500 µl of the JetPRIME buffer. 
Mix well by vortexing the tube, and spin down shortly. 
 
2.3.2) Add 37.5 µl of the JetPRIME reagent, vortex and spin down for one minute at 14,000 x g. 
Incubate the transfection mix 10 min at room temperature. 
 
2.3.3) Add the transfection mix dropwise to the cell culture medium and make sure to pipette 
directly into the medium avoiding contact with the walls of the culture flask. Incubate the flasks 
at 37 °C in a 5% CO2 humidified incubator for 20 - 24 hr. 
 
3. Calcium mobilization assay 
 
3.1) Collect the transfected cells and seed them in 96-well black-walled, clear-bottom plates. 
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3.1.1) Place the PBS, PBS-Trypsin-EDTA and the DMEM transfer medium (500 ml DMEM 
supplemented with 10% dialyzed FBS and 1% P-S) at room temperature half an hour in advance. 
 
3.1.2) Coat the 96-well black-walled, clear bottom plates with 60 µl of PBS with fibronectin 
(0.0025%) per well (5.85 ml PBS and 150 µl fibronectin [0.1%] per plate). Incubate the plates at 
room temperature for 1 hr with the lid on. Remove the solution from the wells and incubate the 
plates again for 1 hr without the lid on at room temperature. Alternatively, it is possible to use 
pre-coated plates for enhanced cell attachment. 
 
3.1.3) Take off the old growth medium from the cells and rinse dead cells off with 3 ml PBS and 
remove the PBS. 
 
3.1.4) Add 3 ml PBS-Trypsin-EDTA, incubate for 1 min, then remove the solution. Note: The 
morphology of the cells changes from star-shaped to sphere-shaped. 
 
3.1.5) Loosen the cells from the bottom of the flask by gentle tapping and collect them by rinsing 
several times with 10 ml of DMEM transfer medium. Transfer the cells into a 50 ml falcon tube. 
 
3.1.6) Count the number of cells per ml (performed with a NucleoCounter here, but a Burker’s 
chamber is acceptable). Add 100 µl of the cell culture in a 1.5 ml microcentrifuge tube. Add 100 
µl lysis buffer and mix by tapping the tube. Add 100 µl stabilizing buffer and mix by tapping. 
 
3.1.7) Fill a NucleoCassette
 
with the cell suspension and count the cells with the counter. 
Multiply the number of cells by three, as the cells were diluted by a factor three when adding the 
lysis and stabilizing buffer in step 3.1.5. 
 
3.1.8) Dilute the cells to a final concentration of 600,000 cells/ml and seed 150 µl of the cells per 
well in the coated plates to obtain a cell density of about 90,000 cells per/well. Avoid air bubbles 
and tap the plate to spread the cells evenly in order to get a contiguous cell layer. Incubate the 
plates at 37 °C in a 5% CO2 humidified incubator for 16-24 hr. 
 
3.2) Load the cells with the fluorescent dye and prepare the compound plate. 
 
3.2.1) Prepare Hank’s balanced salt solution (HBSS)/HEPES/Ca2+/bovine serum albumin (BSA) 
buffer: add 165 µl CaCl2 stock solution (1 M CaCl2 in distilled water [dH2O] – store at room 
temperature), 500 µl HEPES stock solution (1M HEPES in dH2O, pH 7.4 – store at room 
temperature), and 0.05 g BSA to 50 ml HBSS. Note that fatty acid free BSA is used for calcium 
assays, as fatty acids can activate specific receptors, impairing the calcium signal of the receptor 
of interest. 
 
3.2.2) Prepare probenecid solution (100x, 250 mM): dissolve 0.71 g probenecid in 5 ml NaOH (1 
M) and add 50 µl HEPES stock solution and 5 ml of the HBSS/HEPES/Ca
2+
/BSA buffer – 
always prepare fresh solution.  Note: Probenecid inhibits inorganic anion transporters that can 
dislodge Fluo-4 from the cytoplasm, thereby reducing the fluorescent signal. It is recommended 
to perform the dye loading in the presence and absence of probenecid to determine whether 
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inorganic anion transporters present a potential problem in the particular cell lines under 
investigation, as probenecid might even decrease the agonist-mediated signal. 
 
3.2.3) Prepare wash buffer: add 500 µl probenecid solution to 50 ml HBSS/HEPES/Ca
2+
/BSA 
buffer, adjust the pH to 7.4 and filtrate the buffer solution. Always prepare fresh buffer, and 50 
ml buffer per plate is required. 
 
3.2.4) Prepare 10% pluronic acid solution: mix 50 µl pluronic acid (20% w/v in dimethyl-
sulfoxide [DMSO]) with 50 µl DMSO – if crystallization occurs, heat to 37 °C and always 
prepare fresh solution. 
 
3.2.5) Prepare Fluo-4 AM solution (1mM): add 44 µl 10% pluronic acid solution to a vial that 
contains 50 µg Fluo-4 AM and vortex until it is completely dissolved. Avoid exposure to light to 
prevent bleaching of the fluorophore. 
 
3.2.6) Prepare loading buffer: add 8.8 ml DMEM supplemented with 10 mM HEPES and 2.5 
mM probenecid (pH 7.4) to the Fluo-4 AM solution (44 µl) and vortex. Always use fresh buffer. 
 
3.2.7) Discard medium from the cells, wash the cells with 200 µl PBS per well, and remove PBS. 
 
3.2.8) Add 55 µl loading buffer per well and incubate for 1 hr at room temperature. Wrap the 
plate in aluminum foil to prevent exposure of the plate to light. 
 
3.2.9) Make sure to dry the compounds before the screen if they are dissolved in solvents that are 
detrimental (e.g. acetonitrile) for the cellular expression system. 
 
3.2.10) Solubilize the peptides in wash buffer in siliconized 1.5 ml microcentrifuge tubes. 
Prepare a dilution series to perform a concentration-response analysis and to determine the EC50 
value of a ligand. Add 70 µl of the ligand in the corresponding well of the compound plate (V-
shaped 96-well plates) and include positive (endogenous agonist) and negative controls (wash 
buffer) on each plate. Note: if a compound is not soluble in the wash buffer, one can try other 
solvents that are not harmful for the cells under investigation, such as water or solutions that 
emulsify and solubilize oils and other water-insoluble substances (e.g. Kolliphor EL). 
 
3.2.11) Measure all samples in triplicate. Keep in mind that 50 µl of a ligand from the compound 
plate will be transferred into a well with 100 µl wash buffer of the cell plate during the assay, so 
prepare the compounds at 3x their desired final concentration. 
 
3.2.12) Discard the loading buffer from the cell plate and add 100 µl wash buffer to each well. 
Incubate the plate 15 min at room temperature and prevent exposure to light. 
 
3.2.13) Discard the wash buffer from the cell plate and add 100 µl new wash buffer to each well. 
 
3.2.14) Incubate the cell plate, the compound plate, and a tip rack (96-Well, station device Pipet 
Tips) for 15 min at 37 °C. 
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4. Assay on the station device 
 
4.1) Create and load the desired protocol file with the software and activate the temperature 
control unit for the reading chamber. Here, measure calcium responses at 37 °C for 2 min one 
row at a time with 1.52 sec interval between successive readings (measuring a complete 96-well 
plate takes approximately 25 min) at 525 nm. Set the excitation of Fluo-4 to 488 nm and transfer 
a total volume of 50 µl of compound to the cell plate, 18 sec after the reading start, with the 
dispense speed set at 26 µl/sec and a pipette height of 135 µl. 
 
4.2) Position the compound and cell plate, and the tip rack in the appropriate drawers of the 
station device. 
 
4.3) Perform a single read of the cell plate at the same excitation and emission wavelength in the 
ENDPOINT mode, before starting the actual screen in FLEX mode. Note: This measurement 
gives relative fluorescence unit (RFU) values and allows detecting variability between wells of 
the plate. Values between 20,000 and 40,000 are considered as acceptable. 
 
4.4) Start the assay and analyze the data with the software. 
 
REPRESENTATIVE RESULTS: 
Concentration series ranging from 50 µM to 0.001 nM were tested for all four Drosophila sNPF 
peptides (Drome-sNPF-1: AQRSPSLRLRFamide, Drome-sNPF-2: SPSLRLRFamide, Drome-
sNPF-3: PQRLRWamide, Drome-sNPF-4: PMRLRWamide) on HEK293T cells that transiently 
express the Drosophila sNPF receptor and the promiscuous Gα16 subunit. The GPCR was 
activated by all four peptides in final concentrations up to 0.1 nM, and receptor activation was 
concentration-dependent. Figure 2 depicts the graphs corresponding to one of three replicas of 
the Drome-sNPF-1 concentration series. The negative control (wash buffer) did not induce a 
fluorescent signal, while the positive control (PAR1 – 1 µM) elicited strong activation of the 
endogenous protease-activated receptor-1, leading to a high fluorescent signal (± 30,000 RFU). It 
should be noted that a deviation of the typical curve may indicate abnormalities. For example, an 
ongoing rise of the curve without returning to the baseline might be related to non-receptor-
mediated signals, such as the presence of calcium ionophores, or a disrupted lipid bilayer causing 
calcium leaks. 
 
The software allows entering formulas to determine the percentage of activation or the standard 
errors of the different concentrations among others. The resulting data are used to compose 
preliminary concentration-response curves to estimate the EC50 values, as shown for the four 
Drome-sNPF peptides in Figure 3. The curves of Figure 3 also include the data for the negative 
control where the concentration series of the Drome-sNPF peptides were tested on HEK293T 
cells transfected with an empty pcDNA3.1 vector. The results indicate that the addition of the 
peptides to these cells have no effect on endogenous receptors, but indeed activate the receptor of 
interest. The fluorescence-based calcium mobilization assay was then repeated three times 
independently. Based on the preliminary concentration-response curves of the initial screen, the 
tested concentrations were adapted to cover the dynamic range of the curve (Figure 4). The EC50 
values of Drome-sNPF-1 (2.04 ± 1.48 nM [95% confidence interval]), Drome-sNPF-2 (5.89 ± 
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3.74 nM), Drome-sNPF-3 (5.55 ± 3.95 nM) and Drome-sNPF-4 (0.50 ± 1.01 nM) are similar, 
indicating that they are equally potent to activate the receptor. 
 
Figure Legends: 
 
Figure 1. Overall scheme of the fluorescence-based calcium mobilization assay. 
Automated liquid handling and simultaneous fluorescence measurements are performed with the 
station device microplate reader, driven by the software. The station device contains three 
drawers: one for the cell plate, compound plate and tip rack. The build-in pipettor transfers 
compounds from one column of the compound plate to the corresponding column of the cell 
plate (step 1). Each well of the cell plate contains a monolayer of HEK293T cells that have been 
co-transfected with the GPCR of interest and the promiscuous Gα16 subunit. When a compound 
activates the receptor, the Gα16-bound GDP is replaced by GTP. The Gα16 subunit subsequently 
dissociates from the Gβγ complex and activates phospholipase Cβ (PLCβ), which in turn 
hydrolyzes phosphatidylinositol bisphosphate (PIP2) resulting in diacylglycerol (DAG) and 
inositol trisphosphate (IP3). IP3 activates IP3-dependent calcium channels present in the 
membrane of the endoplasmic reticulum, inducing the release of calcium into the cytoplasm. The 
interaction of calcium with Fluo-4 (with which the cells are loaded prior to compound addition) 
results in a fluorescent signal (step 2). The software presents the results as relative fluorescent 
unit (RFU) values in function of time, and peak heights correlate with the ligand concentration in 
a concentration-dependent manner. These data can then be converted into a concentration-
response curve to determine the EC50 value of a ligand-receptor pair (step 3). 
 
Figure 2. Graphical output of the software for a receptor-mediated fluorescence response 
of a concentration series. 
Twelve final concentrations (ranging from 50 µM to 0.001 nM) of the Drome-sNPF-1 peptide 
were tested on the Drome-sNPF receptor. Activation is expressed in relative fluorescent unit 
(RFU) values. The upper graph gives the results of the six highest concentrations and the lower 
graph of the six lowest concentrations. The positive control (+) is PAR1 (1 µM) and the negative 
control (-) is wash buffer. 
 
Figure 3. Preliminary concentration-response curves of Drosophila sNPF peptides 
determined by a single fluorescence-based calcium mobilization assay. 
The concentration-response curves of the Drosophila sNPF receptor transiently expressed in 
HEK293T cells for the four Drosophila sNPF peptides are shown in blue. For the negative 
controls (shown in red), peptides were tested on HEK293T cells transfected with an empty 
pcDNA3.1 vector. The fluorescent responses are shown as relative (%) to the highest value 
(100% activation). The curves are the result of one experiment in which each concentration 
series was measured in triplicate. The vertical bars represent standard errors of the mean (SEM), 
which sometimes are smaller than the used symbols (in that case, only the symbols are depicted). 
EC50 values are shown with their 95% confidence intervals. 
 
Figure 4. Concentration-response curves and corresponding EC50 values of Drosophila 
sNPF peptides determined by three independent fluorescence-based calcium mobilization 
assays. 
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The concentration response curves of the Drosopihla sNPF receptor transiently expressed in 
HEK293T cells for the four Drosophila sNPF peptides are the result of three independent 
measurements each performed in triplicate (n ≥ 9). The fluorescent responses are shown as 
relative (%) to the highest value (100% activation). Asterisks indicate concentrations for which n 
≤ 9. Error bars indicate SEM, which sometimes are smaller than the used symbols (in that case, 
only the symbols are depicted). EC50 values are shown with their 95% confidence intervals. 
 
DISCUSSION: 
The fluorescence-based calcium mobilization assay was successfully applied to confirm the 
functional characterization of the Drosophila sNPF peptidergic signaling system, which was 
already performed by Mertens et al. with a bioluminescence assay and by Feng et al. with an 
electrophysiological assay
13,15
. The EC50 values obtained with the fluorescence assay in 
HEK293T cells are about 10-fold less than those obtained with the bioluminescence assay 
performed in CHO cells (Drome-sNPF-1: fluo = 2.04 nM, lumi = 51 nM; Drome-sNPF-2: fluo = 
5.89 nM, lumi = 42 nM; Drome-sNPF-3: fluo = 5.55 nM, lumi = 31 nM; Drome-sNPF-4: fluo = 
0.50 nM, lumi = 75 nM). These variations can be explained by several factors, including the fact 
that one of the used expression systems may be better suited for functional expression of a given 
receptor, or the folding of some receptors can be less efficient in certain cell types. The EC50 
values of all four Drome-sNPF peptides are in the nanomolar range when tested on their receptor 
with both the fluorescence and the bioluminescence assay, generally supporting the physiological 
relevance of their peptide-receptor interaction in vivo. 
 
Note that no transfection control with a receptor for which the activating ligand is known was 
included in the screen presented here, because the Drosophila sNPF signaling system is normally 
the transfection control in experimental setups. The positive control with an endogenous ligand 
of the HEK293T cells (PAR1) and the negative control (wash buffer) were included in the screen. 
The results of PAR1 showed that the cells were in a good condition. The negative control (wash 
buffer) did not elicit a fluorescent signal, which indicates that the medium in which the peptides 
are dissolved was free of any contaminants that could influence the results. 
 
The previously characterized Drosophila sNPF signaling system was used here to explain the 
fluorescence-based calcium mobilization assay. For this purpose, concentration series of the 
activating ligands were tested immediately. However, when an orphan receptor is brought to 
overexpression in a screening assay to test a library containing hundreds of compounds, it is 
recommended to first screen with relatively high final concentrations of the ligands (e.g. 10 or 1 
µM). Following the detection of an activating compound, a dilution series of that compound can 
be screened in order to compose a concentration-response curve and to determine the EC50 value. 
 
Once the activating ligand of a receptor is determined, the intracellular signaling pathway can be 
further investigated by adapting the protocol. The assay can be performed as described above, 
but without co-transfecting the Gα16 subunit. When a calcium response is measured, it means 
that the receptor couples with an endogenous Gαq subunit of the cellular expression system. 
When no fluorescent signal is observed, protocols to measure changes in concentrations of other 
secondary messengers (e.g. cAMP) can be applied. 
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Structure-activity relationship (SAR) studies can also be carried out to define the peptide’s core 
sequence required for receptor activation. First, truncated sequences are assessed to define the 
minimal amino acid sequence of the peptide that is still able to activate the receptor. Next, 
peptides can be tested in which systematically every amino acid has been substituted for an 
alanine residue. Testing synthetic alanine-substitution series on the receptor allows to determine 
the importance of each of the amino acids for receptor activation
24,25
. 
 
Despite its frequent use and proven efficacy, it has to be emphasized that the assay described 
here may need some adaptations to gain optimal results for specific receptors of interest. The 
Gα16 subunit has the advantage that it binds to most GPCRs, but may also have a dominant-
negative effect on receptors that endogenously couple via Gαq
22
. In this case, it may be useful to 
test different combinations of G proteins during the optimization of a novel calcium assay and to 
compare the results for Gαq-coupled receptors in the absence or presence of Gα16. Alternative 
assays that are independent of the interacting G protein to detect receptor activation can also be 
performed, such as the translocation of GFP-labeled arrestin, or the detection of changes in 
membrane potential (e.g. by the FLIPR Membrane Potential Assay Kit). Besides the Fluo-4 AM 
used here, a wide array of other calcium-sensitive fluorophores, each with its own spectral and 
chemical properties, is available. The most appropriate fluorophore can be selected based on the 
GPCR, cell type and the available plate reader, but experimental verification is necessary. The 
amounts of transfected DNA and the DNA/transfection reagent ratio need to be determined for 
each receptor-transfection reagent-cell line combination. Finally, it should be kept in mind that 
cells in continuous culture only allow 20 – 25 usable passages to perform the screening assays. 
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Name of Material/ Equipment Company Catalog Number Comments/Description
HEK293T cells
Dulbecco's Phosphate Buffered 
Saline (PBS)
Sigma-Aldrich D8537
Trypsin-EDTA solution (0.25%) Sigma-Aldrich T4049
Ethylenediaminetetraacetic acid 
disodium salt dihydrate (EDTA)
MP Biomedicals 195173
Dulbecco's Modified Eagle's 
Medium - high glucose  (DMEM)
Sigma-Aldrich D5796
Fetal Bovine Serum (FBS) Sigma-Aldrich F7524
Penicillin-Streptomycin (P-S) Sigma-Aldrich P4333
jetPRIME
Polyplus 
transfection
114-01
FuGENE HD Transfection 
Reagent (Promega); 
Lipofectamine LTX & Plus 
Reagent (Life 
technologies)
Dialyzed Fetal Bovine Serum (FBS) Sigma-Aldrich F0392
Fibronectin from human plasma Sigma-Aldrich F0895
Reagent A100, Lysis buffer Chemometec 910-0003
Reagent B, Stabilizing buffer Chemometec 910-0002
CaCl2 Sigma-Aldrich C3881
HEPES Sigma-Aldrich H4034
Bovine Serum Albumin (BSA) Sigma-Aldrich A4503
HBSS buffer: Hank's Balanced Salt 
Solution
Sigma-Aldrich H8264
Probenecid Sigma-Aldrich P8761
NaOH (1 M) Vel 2781
Pluronic acid Invitrogen P-3000MP
Dimethyl-sulfoxide (DMSO) Sigma-Aldrich D8418
Fluo-4 AM Invitrogen F14201
Fluo-3, Rhod-2, Fluo-5, 
Calcium Green-1,.. 
(Invitorgen)
TPP tissue culture flasks (T-75 and 
T-150)
Sigma-Aldrich
Z707503 and 
Z707554
FlexStation device
Molecular 
Devices
NOVOstar (BMG 
Labtechnologies); FLIPR 
(Fluorometric Imaging 
Plate Reader) (Molecular 
Devices)
Black-walled polystyrene plates 
(96 wells) with clear bottom
Greiner Bio-One 655090
Corning 96 well flat clear 
bottom black polystyrene 
poly-D-lysine coated 
microplates
NucleoCassette Chemometec 941-0001
NucleoCounter NC-100 Chemometec
Microcentrifuge tubes, siliconized BioCision BCS-2470
Polystyrene V-shaped 96-well 
plates
Greiner Bio-One 651101
96-Well, FlexStation Pipet Tips
Molecular 
Devices
9000-0912
Soft Max Pro software
Molecular 
Devices
